Background
==========

Omalizumab is a humanized antibody utilized for patients with moderate/severe allergic asthma. There is an estimated risk of anaphylaxis to omalizumab in 0.1% of patients. Omalizumab should be received in the subcutaneous tissue of the mid-posterolateral upper arm. There may be an increased risk of anaphylaxis if injections are received intramuscularly (IM). In our clinic, omalizumab is given with *BD Eclipse™ Needle*, which is routinely provided with the drug and has needle length 16mm. If a patient has a skin to muscle depth (STMD) less than 16mm, there is a risk of omalizumab being injected IM.

Methods
=======

We reviewed charts in an allergy clinic where an ultrasound of the left posterolateral arm was completed to measure STMD. Patients were divided into two groups based on their STMD (\>16 mm and ≤16 mm) and baseline characteristics were compared. We conducted multivariable linear regression with age, sex, BMI and race. The percentages of patients with STMD greater than 4 mm, 6 mm, 8 mm, 10 mm, and 12 mm were determined.

Results
=======

Ultrasounds were completed on 40 patients receiving omalizumab. Three (7.5%) patients examined had \>16 mm of STMD. Baseline characteristics were consistent between the groups except for BMI (*p* \< 0.05). Sex and BMI correlated with STMD based on the linear regression analysis. Also, 35 (87.5%) patients had \>4 mm STMD.

Conclusion
==========

With provided omalizumab needles, the risk of anaphylaxis may be increased as the injections may be given IM. By reducing the needle length to 4 mm, the risk will likely be reduced.
